Literature DB >> 7813329

Contemporary pulmonary embolism thrombolysis.

S Z Goldhaber1.   

Abstract

Lack of familiarity with pulmonary embolism (PE) thrombolysis is understandable because most hospitals treat just a few patients each year with recognized massive PE. Therefore, most physicians are inexperienced in administering PE thrombolysis, even though they utilize these agents routinely for acute myocardial infarction. Current estimates are that no more than 10% of patients with PE receive thrombolysis in the United States. This situation may be changing now, because PE thrombolysis appears to have expanded indications. Contemporary PE thrombolysis can now be given with simpler, less expensive protocols than were previously available. In the past, this treatment strategy had been rightly regarded as a heroic measure that consumed hospital resources and physicians' time. Today, PE thrombolysis can be applied with a 2 week "time window," no mandatory angiography in many cases, a brief infusion through a peripheral vein, and no special laboratory tests.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7813329     DOI: 10.1378/chest.107.1_supplement.45s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis.

Authors:  B Yung; J S Elborn; I A Campbell; Y Summers; M Beckles; A A Woodcock
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis.

Authors:  K L Fraser; H Grosman; R H Hyland; D E Tullis
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

3.  Systemic thrombolysis in acute pulmonary embolism: also a matter of "time".

Authors:  Marco Zuin; Loris Roncon
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

4.  Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.

Authors:  Ameya R Kirtane; Tanmoy Sadhukha; Hyunjoon Kim; Vidhi Khanna; Brenda Koniar; Jayanth Panyam
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

5.  Pulmonary Embolism Thrombolysis Improves Survival in Massive Pulmonary Embolism.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.